Engineered immune cells take aim at High-Risk multiple myeloma

NCT ID NCT03549442

Ongoing Disease control Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This phase 1 trial tests a new approach for people with high-risk multiple myeloma who are already responding to their first or second line of therapy. The study uses a patient's own immune cells, engineered to recognize and attack the cancer (CART-BCMA), sometimes combined with another type of engineered cell (huCART19). The goal is to see if this consolidation therapy is safe and can improve outcomes by eliminating remaining cancer cells.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CART-BCMA and huCART19 (CAR T-cells targeting BCMA and CD19)
What this could lead to: If successful, this could offer a powerful new treatment option for high-risk multiple myeloma, potentially leading to deeper and more durable remissions.
What could go wrong: This is an early phase 1 trial with a small number of participants, so safety and effectiveness are not yet proven. CAR T-cell therapy can cause serious side effects like cytokine release syndrome and neurological problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Show contact details

Locations

Univ. of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.